The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer.
Eighty-seven postmenopausal patients have been randomised to receive either radiotherapy or Nolvadex (tamoxifen) as first line treatment for locally advanced (stage III) breast cancer. After a median follow-up of two years no significant differences have been found in the rate of progression of local disease, the time to development of overt metastases or survival.
Williams
M R
MR
City Hospital, Nottingham, U.K.
Gilson
D
D
Marsh
L
L
Morgan
D A
DA
Nicholson
R I
RI
Elston
C W
CW
Griffiths
K
K
Blamey
R W
RW
D001943:Breast Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D014456:Ulcer / Q000209:etiology
D011960:Receptors, Estrogen; D013629:Tamoxifen